SRX 0.00% $33.55 sirtex medical limited

spanner in the works

  1. 779 Posts.
    lightbulb Created with Sketch. 135
    Takes a long time to get a drug or treatment into the market but might this ultimately put a cap on where SRX wants to go?

    Antibody fights prostate cancer
    (UKPA) 6 hours ago
    A miracle molecule has been discovered that offers the hope of saving men with currently incurable prostate cancer.
    The "monoclonal" antibody selectively targets both early-stage and advanced tumours.
    As well as attacking the disease directly, it also helps the immune system to identify and destroy cancer cells.
    In addition, tagging the molecule with a radioactive marker could enable doctors to track spreading prostate cancer, revealing precisely where in the body it is growing. Tests in mice showed that the antibody, known as F77, wiped out 85% of one type of highly aggressive prostate cancer. Tumours allowed to grow to a large size were also dramatically reduced in volume.
    Each year around 35,000 men in the UK are diagnosed with prostate cancer, and 10,000 die from the disease.
    Initially, spreading prostate cancer can be kept under control with therapies that prevent tumour growth being fuelled by androgen male hormones. But eventually most prostate cancers stop being hormone-sensitive. Few treatment options are then possible and progress of the disease is rapid and lethal.
    Up to 45% of patients with local prostate cancer relapse after curative treatments such as surgery and radiotherapy, and their disease begins to spread, or "metastasise". The five-year survival rate for patients with metastatic prostate cancer is only 34%.
    Although the new research is at a very early stage, it raises the prospect of an effective treatment for non-hormone-sensitive advanced prostate cancer for the first time.
    Writing in the journal Proceedings of the National Academy of Sciences, the US scientists said the F77 antibody showed "promising potential for diagnosis and treatment of prostate cancer, especially for androgen-independent metastatic prostate cancer".
    The researchers, led by Dr Mark Greene from the University of Pennsylvania School of Medicine in Philadelphia, pointed out that while antibodies were already being used to tackle other diseases such as lymphoma and breast cancer, those suitable for use against prostate cancer were rare. Two under investigation were both ineffective against many advanced non-hormone-sensitive cancers. F77 on the other hand targeted the most aggressive cancers and responded to those both sensitive and insensitive to male hormones.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.